TY - JOUR
T1 - Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma
AU - Berzaczy, Dominik
AU - Fueger, Barbara
AU - Hoeller, Christoph
AU - Haug, Alexander R
AU - Staudenherz, Anton
AU - Berzaczy, Gundula
AU - Weber, Michael
AU - Mayerhoefer, Marius E
N1 - Funding Information:
The study was supported by the Jubilaeumsfonds of the Oesterreichische Nationalbank (OeNB) project number 16888.
Publisher Copyright:
© 2019, World Molecular Imaging Society.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - PURPOSE: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [18F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma.PROCEDURES: We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed.RESULTS: Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma.CONCLUSIONS: Whole-body [18F]FDG-PET/MRI appears to be comparable to [18F]FDG-PET/CT for lesion detection in patients with malignant melanoma.
AB - PURPOSE: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [18F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma.PROCEDURES: We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed.RESULTS: Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma.CONCLUSIONS: Whole-body [18F]FDG-PET/MRI appears to be comparable to [18F]FDG-PET/CT for lesion detection in patients with malignant melanoma.
KW - Female
KW - Fluorodeoxyglucose F18/chemistry
KW - Humans
KW - Magnetic Resonance Imaging/methods
KW - Male
KW - Melanoma/diagnostic imaging
KW - Middle Aged
KW - Multimodal Imaging/methods
KW - Neoplasm Metastasis
KW - Positron Emission Tomography Computed Tomography/methods
KW - Positron-Emission Tomography/methods
KW - Prospective Studies
KW - Radiopharmaceuticals/chemistry
KW - Whole Body Imaging/methods
UR - http://www.scopus.com/inward/record.url?scp=85069944015&partnerID=8YFLogxK
U2 - 10.1007/s11307-019-01413-7
DO - 10.1007/s11307-019-01413-7
M3 - Journal article
C2 - 31363965
SN - 1536-1632
VL - 22
SP - 739
EP - 744
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
IS - 3
ER -